Multiple Sclerosis Clinical Trial
Official title:
NIB Repository Protocol
Background:
- Information and samples collected from participants in medical research studies can be
useful even after the original study is complete. Researchers can use the information and
samples to learn more about multiple sclerosis or other immune system disorders. They can
also be used for research into other disorders. Researchers would like to get permission to
use samples collected from older studies to launch new lines of research.
Objectives:
- To look at information and samples from earlier National Institutes of Health
Neuroimmunology Branch studies.
Eligibility:
- People who provided samples and medical information for earlier studies.
Design:
- Researchers will contact people who took part in earlier studies. Researchers will ask
if they can study previously collected data and samples.
- Data and samples may include physical exam data and psychological test results. Imaging
study results are included. Preserved samples of body fluids and tissues may be studied.
These include blood and urine samples.
- No new treatment will be provided as part of this research study.
Purpose
This protocol has the following goals:
1. To enable prospective IRB review of research using human samples and data collected
under other Neuroimmunology Branch (NIB) protocols
2. To enable retrospective review of samples and data from the branch s protocols that have
been terminated prior to full data analysis and publication.
3. To enable continued use of human samples and data collected under NIB protocols in which
some of the Investigators have previously participated.
Subjects
Subjects who previously participated in NIH protocols for whom we have samples or data whose
wishes regarding use of their samples/data for research other than that specified in the
initial protocol is not known, or where we would like to use their samples or data for
purposes other than those they have consented for may be enrolled in this protocol if they
are able to be contacted and consent to additional use of their samples or data.
Study Methods
Data and Sample Ascension
Data and samples may include but are not limited to demographic and personal health
information, psychological or psychiatric testing, blood, urine, cerebrospinal fluid (CSF) or
other body fluids or tissues, results of medical and/or physiological evaluation, and medical
imaging.
Data and samples will enter this protocol from the following terminated IRB-approved
protocols under which all human subject enrollment and participation is complete:
- 01-N-0089 (Rolipram): Safety, tolerability and effects of Rolipram on inflammatory
activity in the central nervous system in multiple sclerosis. A phase II, open label
crossover trial using MRI as an outcome measure.
- 98-N-0069 (APL): Double-blind, randomized, parallel-group, baseline vs. treatment trial
evaluating the safety, tolerability and effect on MRI lesion and immunology parameters
of low vs. high dose CGP 77116 in patients with MS.
- 97-N-0148 (IFG): A 48 week phase II Pilot study of tolerability and effect/efficacy of
subcutaneously administered CEP-151 (rhIGF, Myotrophin) in Multiple Sclerosis (MS)
patients.
- 94-N-0173 (Anti-tac in HAM/TSP): Monoclonal anti-tac antibody immunotherapy of
HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
- 98-N-0160 (Avonex in HAM/TSP): Combined Virological and Immunological Evaluation of
Treatment of Patients with Early HTLV-1 Associated Myleopathy with Recombinant Human
Inteferon-beta1 a.
- 99-N-0169 (Daclizumab/IFN-beta for MS): Effect of the Humanized Monoclonal Antibody
Against the Interleukin-2 Receptor Alpha Subunit (IL-2Ra; Zenapax ) on Inflammatory
Activity in the Central Nervous System (CNS) in Multiple Sclerosis (MS) in a
Baseline-to-Treatment, Cross-Over, MRI-Controlled Single-Center Phase I/II Trial.
- 04-N-0019 (Daclizumab monotherapy for MS): ZAP MS Zenapax[R] (daclizumab) Administered
to Patients with Multiple Sclerosis: Effect of intravenously administered humanized
monoclonal antibody against the interleukin-2 receptor alpha subunit (daclizumab) on
inflammatory activity in the central nervous system in multiple sclerosis patients in a
baseline-to-treatment, cross-over, MRI-controlled single-centre phase II trial.
- 05-N-0039 (3T Cortical imaging): An Exploratory Study on Detection of Cortical Damage in
Patients with Multiple Sclerosis Using Magnetic Resonance Imaging.
- 06-N-0154 (7T): An Exploratory Study on Detection of Cortical and White Matter Damage in
Patients with Multiple Sclerosis Using Magnetic Resonance Imaging at 7 Tesla.
- 07-N-0014 (Cognitive MRI): The use of Magnetic Resonance Imaging to investigate cortical
damage in Patients with Multiple Sclerosis and correlation with Cognitive Dysfunction.
- 02-N-N196 (Stem Cells): Immunological mechanisms of immune ablation and autologous
hematopoietic stem cell transplantation in secondary progressive multiple sclerosis.
- 07-N-0092 (PET): PET Evaluation of brain peripheral benzodiazepine receptors using
[11C]PBR28 in patients with multiple sclerosis (MS).
- 76-N-0021: Clinical, immunological and virological assessment of patients with multiple
sclerosis.
- 81-N-0184: Immunogenetic studies of the human cellular immune response
- 15-N-0117: A Phase I Study of Oral Guanabenz for Multiple Sclerosis
- 15-N-0183: Anakinra, a recombinant human IL-1 receptor antagonist for neuroinflammation
in HIV-1 infection
- 04-N-0071: Phase I/II Study of HTLV-I-Associated Myelopathy / Tropical Spastic
Paraparesis
(HAM/TSP) Using the Humanized MiK- <=-1 Monoclonal Antibody Directed Toward the IL-2/IL-
15R <= Subunit (CD122) that Blocks IL-15 Action
-11-N-0261: Evaluation of skeletal muscle, cardiac, and diaphragm imaging biomarkers for
GSK2402968 effects in ambulatory boys with Duchenne muscular dystrophy
-14-N-0051: A Two-part Placebo-controlled study to evaluate the safety, tolerability and
preliminary efficacy of BVS857 in patients with Spinal and bulbar muscular atrophy (SBMA)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|